Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. (Nasdaq: BMEA) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity, and its news flow reflects this focus on metabolic disease. Company updates frequently center on the progress of its two main investigational programs: icovamenib, an oral covalent menin inhibitor for insulin-deficient diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist candidate for obesity and related metabolic disorders.
News items for BMEA commonly include clinical trial milestones, such as Phase II data readouts for icovamenib in type 2 diabetes, long-term follow-up results, and the initiation or advancement of studies like COVALENT-111, COVALENT-121, COVALENT-211, COVALENT-212, and GLP-131. Biomea Fusion also reports on preclinical findings, including combination data for icovamenib with GLP-1–based therapies and weight-loss and pharmacology data for BMF-650 in animal models.
Investors following BMEA news will also see corporate and financial announcements, such as quarterly financial results, cost-management updates, and underwritten offerings of common stock and warrants. The company regularly issues press releases about its participation in scientific and investor conferences, including oral presentations at diabetes and obesity meetings and fireside chats at healthcare investment conferences.
This news page aggregates these disclosures so readers can track Biomea Fusion’s clinical progress, scientific presentations, financing activities, and other material events. For those monitoring the development of investigational therapies in diabetes and obesity, the BMEA news feed offers a centralized view of the company’s reported milestones and public communications over time.
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has appointed Julianne Averill to its Board of Directors, effective July 22, 2025. Averill, who will serve on the Audit Committee, brings over 20 years of experience in life sciences and digital health, currently serving as Managing Director at Danforth Advisors.
The appointment comes as Bihua Chen steps down after more than four years on the board. Averill's expertise includes capital markets, M&A, and operational scale, with involvement in transactions exceeding $10 billion in aggregate value. She holds both B.S. and M.S. degrees from California State University, along with CPA licensure and NACD Directorship Certification.
- 24 patients enrolled, with 15 having FLT3 mutations
- 81.8% of evaluable patients showed clinical activity
- 77.8% demonstrated decreased bone marrow blasts
- Median overall survival of 3.48 months vs. historical 2.1 months
- Well-tolerated safety profile with no treatment-related discontinuations
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to two new employees as part of their inducement package. The grants, approved on March 23, 2025, by the compensation committee, allow the purchase of a total of 30,000 shares of common stock.
The stock options will vest quarterly over a four-year period, with 1/16 of the shares vesting each quarter, contingent on continued employment. These awards were issued under Biomea's 2023 Inducement Equity Plan, which was adopted by the board on November 17, 2023, and comply with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants for new employees.
Biomea Fusion (BMEA) announced Q4 and full year 2024 financial results, highlighting significant progress in its diabetes and obesity programs. The company appointed Mick Hitchcock as Interim CEO and shifted focus exclusively to metabolic disorders, terminating oncology trials. Key highlights include:
The COVALENT-111 study showed promising results for icovamenib in type 2 diabetes, achieving a 1.47% HbA1c reduction in severe insulin deficient patients and 53% increase in C-peptide levels. The drug demonstrated durability and good tolerability with no serious adverse events.
Financial results show cash position of $58.6 million as of December 31, 2024. Net loss was $29.3 million for Q4 2024 and $138.4 million for full year 2024. R&D expenses were $118.1 million for 2024, up from $102.5 million in 2023.
Key 2025 milestones include FDA discussions for late-stage development, 52-week COVALENT-111 data, COVALENT-112 open label data, and BMF-650 IND submission.